S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:APTX

Aptinyx (APTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.09
$0.10
50-Day Range
$0.06
$0.10
52-Week Range
$0.01
$0.72
Volume
231,100 shs
Average Volume
1.32 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APTX stock logo

About Aptinyx Stock (NASDAQ:APTX)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

APTX Stock News Headlines

Patrick J Heron's Net Worth
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Best Noise-Canceling Headphones for 2024
Aptinyx Inc APTX
North American Morning Briefing: Concerns About -2-
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Aptinyx (NASDAQ: APTX)
H.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)
Aptinyx Inc. (NASDAQ: APTX)
Aptinyx Inc. (APTX)
What 4 Analyst Ratings Have To Say About Aptinyx
See More Headlines
Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$0.57 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.27
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Craig R. Jalbert CIRA (Age 61)
    Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director
  • Mr. Patrick Flavin
    Senior Manager of Corporate Development & Investor Relations
  • Ms. Molly Dir
    Vice President of Human Resources
  • Dr. Kathryn King Ph.D.
    Senior Vice President of Clinical & CMC Operations
  • Mr. Tim Noffke
    VP of Program Management & Chief of Staff
  • Dr. Harald Murck M.D.
    Ph.D., Vice President of Clinical & Medical Affairs

APTX Stock Analysis - Frequently Asked Questions

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). During the same quarter last year, the business earned ($0.24) earnings per share.

What other stocks do shareholders of Aptinyx own?
When did Aptinyx IPO?

Aptinyx (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

This page (NASDAQ:APTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners